Qiagen (NYSE:QGEN), a German provider of sample and assay technologies, has received emergency use authorisation for a new COVID-19 test from the US drugs regulator FDA, Reuters news agency reported on Monday.
The company was quoted as stating: "This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minute."
BioDlink makes first international shipment of bevacizumab to Colombia
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress